Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascelia Pharma AB ( (SE:ACE) ) has shared an announcement.
Ascelia Pharma AB has successfully completed a directed share issue, raising approximately SEK 30 million through the issuance of 8,571,000 new ordinary shares at SEK 3.50 per share. This strategic move aims to strengthen the company’s financial position, support partnering activities, and extend its cash runway into Q4 2026, aligning with the anticipated FDA response on its new drug application. The decision to proceed with a directed share issue, as opposed to a rights issue, was made to efficiently diversify the shareholder base, minimize costs, and mitigate risks associated with market volatility.
More about Ascelia Pharma AB
Ascelia Pharma AB is a company operating in the pharmaceutical industry, focusing on developing and commercializing novel drugs for patients with rare oncology-related conditions. The company’s primary market focus is on providing innovative treatments that address unmet medical needs in the oncology sector.
YTD Price Performance: 33.73%
Average Trading Volume: 1,055,913
Technical Sentiment Signal: Sell
Current Market Cap: SEK453.1M
See more insights into ACE stock on TipRanks’ Stock Analysis page.